MX2020009411A - Capsula resistente al abuso. - Google Patents
Capsula resistente al abuso.Info
- Publication number
- MX2020009411A MX2020009411A MX2020009411A MX2020009411A MX2020009411A MX 2020009411 A MX2020009411 A MX 2020009411A MX 2020009411 A MX2020009411 A MX 2020009411A MX 2020009411 A MX2020009411 A MX 2020009411A MX 2020009411 A MX2020009411 A MX 2020009411A
- Authority
- MX
- Mexico
- Prior art keywords
- abuse
- capsule
- active pharmaceutical
- abuse resistant
- susceptible active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Zoology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención está dirigida a una cápsula o relleno de una cápsula de liberación inmediata y liberación prolongada que mitiga el abuso de los ingredientes farmacéuticos activos susceptibles de abuso por inyección intravenosa directa; el relleno comprende una formulación líquida resistente al abuso parenteral que cuando se mezcla con agua y se calienta resulta en una mezcla turbia, viscosa o burbujeante, que no es inyectable con una jeringa de insulina estándar; el ingrediente farmacéutico activo susceptible de abuso se selecciona del grupo que consiste en opiatos, opioides, tranquilizantes, estimulantes y narcóticos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361794714P | 2013-03-15 | 2013-03-15 | |
US14/204,259 US10420729B2 (en) | 2013-03-15 | 2014-03-11 | Abuse resistant capsule |
PCT/EP2014/055045 WO2014140231A1 (en) | 2013-03-15 | 2014-03-14 | Abuse resistant capsule |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020009411A true MX2020009411A (es) | 2021-11-30 |
Family
ID=51528060
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015012742A MX2015012742A (es) | 2013-03-15 | 2014-03-14 | Capsula resistente al abuso. |
MX2020009411A MX2020009411A (es) | 2013-03-15 | 2014-03-14 | Capsula resistente al abuso. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015012742A MX2015012742A (es) | 2013-03-15 | 2014-03-14 | Capsula resistente al abuso. |
Country Status (15)
Country | Link |
---|---|
US (4) | US10420729B2 (es) |
EP (3) | EP3824878A1 (es) |
JP (4) | JP6395734B2 (es) |
CN (2) | CN105358132B (es) |
AR (1) | AR095343A1 (es) |
AU (3) | AU2014230481B2 (es) |
CA (1) | CA2902501C (es) |
CY (1) | CY1120959T1 (es) |
DK (1) | DK2968129T3 (es) |
ES (1) | ES2700517T3 (es) |
HU (1) | HUE040530T2 (es) |
MX (2) | MX2015012742A (es) |
PT (1) | PT2968129T (es) |
SI (1) | SI2968129T1 (es) |
WO (1) | WO2014140231A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
SI1765292T1 (en) | 2004-06-12 | 2018-04-30 | Collegium Pharmaceutical, Inc. | Formulations of medicines to discourage abuse |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
WO2011009604A1 (en) | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
WO2012028319A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
AR087360A1 (es) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato |
KR20140053158A (ko) | 2011-07-29 | 2014-05-07 | 그뤼넨탈 게엠베하 | 즉시 약물 방출을 제공하는 탬퍼-저항성 정제 |
JP6282261B2 (ja) | 2012-04-18 | 2018-02-21 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 不正使用防止および過量放出防止医薬剤形 |
US10420729B2 (en) * | 2013-03-15 | 2019-09-24 | R.P. Scherer Technologies, Llc | Abuse resistant capsule |
AU2014289187B2 (en) | 2013-07-12 | 2019-07-11 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
MX371372B (es) | 2013-11-26 | 2020-01-28 | Gruenenthal Gmbh | Preparacion de una composicion farmaceutica en polvo por medio de criomolienda. |
US10744131B2 (en) * | 2013-12-31 | 2020-08-18 | Kashiv Biosciences, Llc | Abuse-resistant drug formulations |
CA2947786A1 (en) * | 2014-05-12 | 2015-11-19 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising tapentadol |
CN113197851A (zh) | 2015-05-06 | 2021-08-03 | 辛纳吉勒公司 | 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法 |
WO2017042325A1 (en) | 2015-09-10 | 2017-03-16 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US10662146B2 (en) | 2015-09-15 | 2020-05-26 | Praxis Bioresearch, LLC | Prodrugs of fencamfamine |
US20170312226A1 (en) * | 2016-04-28 | 2017-11-02 | Ascent Pharmaceuticals, Inc. | Pharmaceutical dosage forms |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
CA3039920A1 (en) * | 2016-10-10 | 2018-04-19 | Rhodes Pharmaceuticals L.P. | Pharmaceutical resinate compositions and methods of making and using thereof |
US9931303B1 (en) * | 2017-02-06 | 2018-04-03 | Alcobra Ltd. | Abuse deterrent formulations of amphetamine |
EP3473246A1 (en) | 2017-10-19 | 2019-04-24 | Capsugel Belgium NV | Immediate release abuse deterrent formulations |
CN111867567A (zh) * | 2018-02-26 | 2020-10-30 | R·P·舍勒科技有限责任公司 | 二甲硅油和洛哌丁胺的乳剂的药物剂型 |
GB201809976D0 (en) * | 2018-06-18 | 2018-08-01 | Neurocentrx Pharma Ltd | Novel formulations |
GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
CN110483669A (zh) * | 2019-08-13 | 2019-11-22 | 天津大学 | 一种基于二烯丙基丙二酰脲的聚合物及其制备方法 |
US20240189241A1 (en) * | 2021-04-01 | 2024-06-13 | R.P. Scherer Technologies, Llc | Phospholipids as anion chelating agents in pharmaceutical formulations |
MX2024003466A (es) * | 2021-09-29 | 2024-06-04 | Ensysce Biosciences Inc | Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos. |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8926612D0 (en) | 1989-11-24 | 1990-01-17 | Erba Farmitalia | Pharmaceutical compositions |
US20030118641A1 (en) * | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
US6340471B1 (en) | 1999-12-30 | 2002-01-22 | Alvin Kershman | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
US6541025B1 (en) | 1999-12-30 | 2003-04-01 | Shear/Kershman Laboratories, Inc. | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
CA2455420A1 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique, S.A. | Compositions and methods to prevent abuse of opioids |
US20030059397A1 (en) | 2001-09-17 | 2003-03-27 | Lyn Hughes | Dosage forms |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
CA2491572C (en) | 2002-07-05 | 2010-03-23 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
US20050191244A1 (en) * | 2002-10-25 | 2005-09-01 | Gruenenthal Gmbh | Abuse-resistant pharmaceutical dosage form |
EP1603597B1 (en) | 2003-03-13 | 2010-01-06 | Controlled Chemicals, Inc. | Oxycodone conjugates with lower abuse potential and extended duration of action |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
US20050271594A1 (en) | 2004-06-04 | 2005-12-08 | Groenewoud Pieter J | Abuse resistent pharmaceutical composition |
ITMI20041317A1 (it) | 2004-06-30 | 2004-09-30 | Ibsa Inst Biochimique Sa | Formulazioni farmaceutiche per la somministrazione sicura di farmaci utilizzati nel trattamento della tossicodipendenza e procedimento per il loro ottenimento |
GB0506982D0 (en) | 2005-04-06 | 2005-05-11 | Mw Encap Ltd | Abuse resistant capsules |
US8252326B2 (en) | 2005-06-01 | 2012-08-28 | Catalent Australia Pty Ltd. | Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10 |
CN101360485B (zh) * | 2005-10-26 | 2013-04-17 | 班纳制药公司 | 作为胶囊填充物的基于亲水性载体的双重控释基质系统 |
JP5406529B2 (ja) * | 2005-10-26 | 2014-02-05 | バナー ファーマキャプス, インコーポレイテッド | カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム |
US9125833B2 (en) | 2005-11-02 | 2015-09-08 | Relmada Therapeutics, Inc. | Multimodal abuse resistant and extended release opioid formulations |
WO2007087452A2 (en) | 2006-01-27 | 2007-08-02 | Theraquest Biosciences, Llc | Abuse resistant and extended release formulations and method of use thereof |
US9265724B2 (en) | 2005-11-07 | 2016-02-23 | Ram B. Murty | Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
US20080027011A1 (en) * | 2005-12-20 | 2008-01-31 | Hassan Nached | Homogeneous paste and gel formulations |
DK2018160T3 (da) | 2006-03-16 | 2012-02-06 | Tris Pharma Inc | Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
US20070281065A1 (en) | 2006-06-06 | 2007-12-06 | Modliszewski James J | Kappa-2 carrageenan composition and products made therefrom |
US8202542B1 (en) | 2007-05-31 | 2012-06-19 | Tris Pharma | Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings |
EP2167049B1 (en) | 2007-06-04 | 2016-08-31 | Shear/Kershman Laboratories, Inc. | Tamper resistant lipid-based oral dosage form for opioid agonists |
US8741918B2 (en) * | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
AU2008347158B8 (en) | 2007-12-06 | 2013-08-22 | Durect Corporation | Oral pharmaceutical dosage forms |
US20110097395A1 (en) | 2008-03-08 | 2011-04-28 | Najib Babul | Oral Pharmaceutical Compositions of Buprenorphine and Method of Use |
US8420700B1 (en) | 2008-06-04 | 2013-04-16 | James M. Bausch | Tamper resistant lipid-based oral dosage form for sympathomimetic amines |
WO2010044842A1 (en) | 2008-10-16 | 2010-04-22 | University Of Tennessee Research Foundation | Tamper resistant oral dosage forms containing an embolizing agent |
FR2939542B1 (fr) | 2008-12-04 | 2012-08-03 | Advanced Track & Trace | Procede et dispositif de protection d'un recipient et etiquette pour leur mise en oeuvre |
PL2379111T3 (pl) | 2008-12-12 | 2013-08-30 | Paladin Labs Inc | Preparaty leków narkotycznych o obniżonym potencjale uzależniającym |
US20120065221A1 (en) | 2009-02-26 | 2012-03-15 | Theraquest Biosciences, Inc. | Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use |
EA031154B1 (ru) * | 2009-03-04 | 2018-11-30 | Эмпликюре Аб | Новый препарат, противодействующий злоупотреблению лекарством |
CA2755808C (en) | 2009-03-18 | 2016-01-19 | Evonik Roehm Gmbh | Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients |
US9125867B2 (en) * | 2010-02-24 | 2015-09-08 | Invincible Biotechnology | Diversion- and/or abuse-resistant compositions and methods for making the same |
AR082167A1 (es) * | 2010-07-14 | 2012-11-14 | Gruenenthal Gmbh | Formas de dosificacion gastrorretentivas |
US20120171277A1 (en) | 2011-01-03 | 2012-07-05 | Royds Robert B | Abuse resistant transdermal drug delivery patch including a release-enhanced antagonist |
WO2013003845A1 (en) | 2011-06-30 | 2013-01-03 | Neos Therapeutics, Lp | Abuse resistant drug forms |
US10420729B2 (en) | 2013-03-15 | 2019-09-24 | R.P. Scherer Technologies, Llc | Abuse resistant capsule |
-
2014
- 2014-03-11 US US14/204,259 patent/US10420729B2/en active Active
- 2014-03-14 WO PCT/EP2014/055045 patent/WO2014140231A1/en active Application Filing
- 2014-03-14 MX MX2015012742A patent/MX2015012742A/es active IP Right Grant
- 2014-03-14 HU HUE14711201A patent/HUE040530T2/hu unknown
- 2014-03-14 JP JP2015562169A patent/JP6395734B2/ja active Active
- 2014-03-14 SI SI201430988T patent/SI2968129T1/sl unknown
- 2014-03-14 AR ARP140101047A patent/AR095343A1/es not_active Application Discontinuation
- 2014-03-14 AU AU2014230481A patent/AU2014230481B2/en not_active Ceased
- 2014-03-14 EP EP20216392.9A patent/EP3824878A1/en active Pending
- 2014-03-14 DK DK14711201.5T patent/DK2968129T3/en active
- 2014-03-14 CN CN201480014915.6A patent/CN105358132B/zh active Active
- 2014-03-14 ES ES14711201T patent/ES2700517T3/es active Active
- 2014-03-14 PT PT14711201T patent/PT2968129T/pt unknown
- 2014-03-14 MX MX2020009411A patent/MX2020009411A/es unknown
- 2014-03-14 EP EP18190832.8A patent/EP3446681B1/en active Active
- 2014-03-14 CN CN201910975199.2A patent/CN110585165B/zh active Active
- 2014-03-14 EP EP14711201.5A patent/EP2968129B1/en active Active
- 2014-03-14 CA CA2902501A patent/CA2902501C/en active Active
-
2016
- 2016-09-06 US US15/257,274 patent/US10744097B2/en active Active
-
2018
- 2018-08-09 AU AU2018214110A patent/AU2018214110B2/en not_active Ceased
- 2018-08-28 JP JP2018159092A patent/JP6820117B2/ja active Active
- 2018-12-03 CY CY181101283T patent/CY1120959T1/el unknown
-
2019
- 2019-09-16 US US16/572,148 patent/US11464747B2/en active Active
- 2019-11-15 AU AU2019264648A patent/AU2019264648B2/en not_active Ceased
-
2020
- 2020-12-29 JP JP2020219732A patent/JP2021073196A/ja active Pending
-
2022
- 2022-07-19 US US17/813,517 patent/US20220362160A1/en active Pending
- 2022-12-09 JP JP2022197405A patent/JP2023051939A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020009411A (es) | Capsula resistente al abuso. | |
ZA202102906B (en) | Liquid protein formulations containing viscosity-lowering agents | |
IL243708A0 (en) | Syringes for mixing pre-filled and filled while using and transferring medicine | |
MX2015012641A (es) | Dispositivo de inyeccion de multiples camaras. | |
WO2012135537A3 (en) | Palm-controlled injectors | |
SG10201902915VA (en) | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents | |
MX338987B (es) | Auto-inyector. | |
BR112017008009A2 (pt) | aparelho e sistema de injeção automático usável | |
EA201791333A1 (ru) | Производные глюкагона с улучшенной стабильностью | |
WO2015034870A3 (en) | Double-chamber mixing syringe and method of use | |
MX2013007492A (es) | Dispositivo para inyectar dosis ajustables de farmaco liquido. | |
MX345256B (es) | Formulaciones estables para inyeccion parenteral de farmacos de molecula pequeña. | |
EA201491702A1 (ru) | Оптимизированные терапевтические агенты для подкожного введения | |
EA201790074A1 (ru) | Автоматическое устройство для введения лекарственного препарата с визуальной индикацией хода процесса введения | |
TN2017000011A1 (en) | Aqueous formulation comprising paracetamol and ibuprofen. | |
FR3036289B1 (fr) | Dispositif d'injection de produit injectable comportant une canule coulissant dans une aiguille et systeme utilisant un tel dispositif | |
MX2016014738A (es) | Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol. | |
EA201591664A1 (ru) | Инъекторное устройство многократного использования для шприца | |
EA201591666A1 (ru) | Инъекторное устройство многократного использования для шприца | |
GEP20196947B (en) | Bremelanotide therapy for female sexual dysfunction | |
MX2021000826A (es) | Composicion farmaceutica estable que comprende undecanoato de testosterona. | |
ECSP15000500A (es) | Solucion de acetaminofen supersaturada inyectable para la administracion por la espina dorsal | |
PL414785A1 (pl) | Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną | |
BR112013016858A2 (pt) | dispositivo para injetar doses ajustáveis de droga líquida | |
CN302586572S (zh) | 无针注射器 |